Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder with
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Metabolic processes can influence disease risk and provide therapeutic targets. By
conducting genome-wide association studies of 1,091 blood metabolites and 309 metabolite …

Abstract Characterization of the genetic landscape of Alzheimer's disease (AD) and related
dementias (ADD) provides a unique opportunity for a better understanding of the associated …

Late-onset Alzheimer's disease is a prevalent age-related polygenic disease that accounts
for 50–70% of dementia cases. Currently, only a fraction of the genetic variants underlying …

Alzheimer's disease is the leading cause of dementia worldwide, but the cellular pathways
that underlie its pathological progression across brain regions remain poorly understood …

The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …

Tau protein is involved in various cellular processes, including having a canonical role in
binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative …

The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has …

Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …